Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TW-37 |
Synonyms | |
Therapy Description |
TW-37 is a third-generation BH3 mimetic that inhibits BCL2, MCL1, and with lesser affinity, BCL-XL, which may result in increased tumor cell apoptosis and increased sensitivity to chemotherapeutics (PMID: 17404107, PMID: 32257914). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TW-37 | BCL-XL inhibitor 14 BCL2 inhibitor 27 MCL1 Inhibitor 18 | TW-37 is a third-generation BH3 mimetic that inhibits BCL2, MCL1, and with lesser affinity, BCL-XL, which may result in increased tumor cell apoptosis and increased sensitivity to chemotherapeutics (PMID: 17404107, PMID: 32257914). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|